Open Access

Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study

  • Authors:
    • Yuichiro Tozuka
    • Makoto Ueno
    • Satoshi Kobayashi
    • Manabu Morimoto
    • Taito Fukushima
    • Yusuke Sano
    • Kuniyuki Kawano
    • Akane Hanaoka
    • Shun Tezuka
    • Hiroyuki Asama
    • Satoshi Moriya
    • Soichiro Morinaga
    • Shinichi Ohkawa
    • Shin Maeda
  • View Affiliations

  • Published online on: September 8, 2022     https://doi.org/10.3892/ol.2022.13495
  • Article Number: 375
  • Copyright: © Tozuka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no reports on the relationship between gemcitabine plus nab‑paclitaxel combination therapy (GnP) and sarcopenia in patients with unresectable pancreatic cancer. The present study analyzed the relationship between overall survival (OS), progression‑free survival (PFS), response rate, disease control rate, adverse events (AEs) and sarcopenia in patients with pancreatic cancer treated with GnP. A total of 121 consecutive patients with advanced pancreatic cancer who received GnP as first‑line chemotherapy between January 2015 and December 2017 were retrospectively analyzed. GnP consisted of 1,000 mg/m2 gemcitabine and 125 mg/m2 nab‑paclitaxel, which were administered on days 1, 8 and 15 every 4 weeks. The skeletal muscle index (SMI) was calculated using bioimpedance analysis (BIA) as an index of sarcopenia prior to GnP. The patients were divided into sarcopenia (n=41) and non‑sarcopenia (n=80) groups using cutoff values of 8.87 and 6.42 kg/m2 for male and female patients, respectively. The sarcopenia and non‑sarcopenia groups had a median OS of 8.1 and 13.9 months, respectively [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.53‑1.20], and a median PFS of 4.3 and 6.3 months, respectively (HR 0.63; 95% CI 0.42‑0.95). The response and disease controls rate were not statistically different between the groups (20 vs. 32%, P=0.20; 81 vs. 80%, P=1.0). In addition, comparison of common grade 3 and 4 AEs between the two groups revealed no statistically significant differences. In conclusion, the results of the present study indicated that SMI obtained by BIA may be a predictor of treatment response and prognosis in patients with advanced pancreatic cancer who undergo GnP.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tozuka Y, Ueno M, Kobayashi S, Morimoto M, Fukushima T, Sano Y, Kawano K, Hanaoka A, Tezuka S, Asama H, Asama H, et al: Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study. Oncol Lett 24: 375, 2022
APA
Tozuka, Y., Ueno, M., Kobayashi, S., Morimoto, M., Fukushima, T., Sano, Y. ... Maeda, S. (2022). Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study. Oncology Letters, 24, 375. https://doi.org/10.3892/ol.2022.13495
MLA
Tozuka, Y., Ueno, M., Kobayashi, S., Morimoto, M., Fukushima, T., Sano, Y., Kawano, K., Hanaoka, A., Tezuka, S., Asama, H., Moriya, S., Morinaga, S., Ohkawa, S., Maeda, S."Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study". Oncology Letters 24.4 (2022): 375.
Chicago
Tozuka, Y., Ueno, M., Kobayashi, S., Morimoto, M., Fukushima, T., Sano, Y., Kawano, K., Hanaoka, A., Tezuka, S., Asama, H., Moriya, S., Morinaga, S., Ohkawa, S., Maeda, S."Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study". Oncology Letters 24, no. 4 (2022): 375. https://doi.org/10.3892/ol.2022.13495